Healthcare Services

Global Tildrakizumab Market Anticipated To Grow To $3.02 Billion By 2030 At 11.4% CAGR

June 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Tildrakizumab Market By 2030?

The tildrakizumab market has witnessed swift expansion in recent years. It is anticipated to grow from $1.76 billion in 2025 to $1.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.7%. This historical growth can be attributed to several factors, including the increasing prevalence of plaque psoriasis, established clinical validation of biologic efficacy, the expansion of specialty dermatology clinics, the growing acceptance of injectable biologics, and the availability of reimbursement support for biologics.

The market for tildrakizumab is projected to experience swift expansion over the coming years, reaching $3.02 billion by 2030, driven by an 11.4% compound annual growth rate (CAGR). This anticipated growth during the forecast period is fueled by several factors, including the rising need for individualized autoimmune treatments, the broadening of indications for biologic pipelines, a heightened emphasis on managing diseases over the long term, the increasing preference for administering biologics at home, and greater financial commitment to immunology research. Key trends expected during this period involve the expanded application of targeted biologic therapies, the growing embrace of il-23 inhibitors, a developing preference for injectable treatments with extended effects, the widening of specialized biologic distribution networks, and a stronger focus on patient-centered treatment approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21301&type=smp

Which Major Factors Are Contributing To The Development Of The Tildrakizumab Market?

The growing prevalence of autoimmune disorders is projected to boost the tildrakizumab market. Autoimmune diseases, characterized by the immune system mistakenly attacking healthy bodily tissues, are on the rise, primarily due to increasing environmental factors such as pollution and chemical exposure. Tildrakizumab addresses these conditions by blocking the IL-23 pathway, which helps reduce inflammation and manage symptoms. For example, in August 2024, Public Health Scotland, a national organization situated in Scotland, reported that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 new patients diagnosed with MS in 2023. This increase in autoimmune disease incidence is therefore a significant factor propelling the growth of the tildrakizumab market.

How Is The Tildrakizumab Market Examined Through Segment Analysis?

The tildrakizumab market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications

2) By Dosage Form: Injectable, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Specialty Clinics, Homecare

Subsegments:

1) By Plaque Psoriasis: Moderate Plaque Psoriasis, Severe Plaque Psoriasis, Treatment-Resistant Plaque Psoriasis

2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis, Enthesitis-related Psoriatic Arthritis

3) By Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications

Which Trends Are Contributing To Changes In The Tildrakizumab Market?

Who Are The Major Companies Operating In The Tildrakizumab Market?

Major companies operating in the tildrakizumab market are Almirall S.A., Sun Pharmaceutical Industries Ltd., Novartis, Pfizer, Eli Lilly, Bristol Myers Squibb, Roche, Merck & Co, Janssen Biotech (Johnson & Johnson), Amgen, GSK, AbbVie, Sanofi, AstraZeneca, Innovent Biologics, Boehringer Ingelheim, LEO Pharma, Kyowa Kirin, Takeda Pharmaceutical, Regeneron Pharmaceuticals, Biocon Ltd.

Access The Complete Tildrakizumab Market Report:

https://www.thebusinessresearchcompany.com/report/tildrakizumab-global-market-report

Which Region Has The Strongest Presence In The Tildrakizumab Market?

North America was the largest region in the tildrakizumab market in 2025. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in the tildrakizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Tildrakizumab Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21301&type=smp

Browse Through More Reports Similar to the Global Tildrakizumab Market 2026, By The Business Research Company

Fishmeal Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fishmeal-global-market-report

Sukuk Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sukuk-global-market-report

Dulaglutide Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dulaglutide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795